StocksMedium•5 November 2026•
1 min read
Quoin Pharmaceuticals Secures $50M Financing and Reports Positive QRX003 Data
Key Facts
1Quoin Pharmaceuticals announced a private placement financing of up to $50.0 million with institutional investors.
2The company reported positive interim data from its Phase 2/3 study of QRX003, achieving statistical significance in key endpoints.
3The FDA cleared the first-ever IND for Peeling Skin Syndrome (PSS) and granted Fast Track designation to QRX003.
Quoin Pharmaceuticals announced a private placement financing of up to $50.0 million with institutional investors to fund its ongoing operations and clinical pipeline. The company reported in a statement via GlobeNewswire that it achieved positive interim data from its Phase 2/3 study of QRX003 for Netherton Syndrome, reaching statistical significance in key endpoints.
QNRX closed at $4.02 on November 4, 2026, prior to the company disclosing that the FDA cleared the first-ever Investigational New Drug application for Peeling Skin Syndrome (PSS). Additionally, the FDA granted Fast Track designation to QRX003 for PSS, while the European Medicines Agency (EMA) granted the candidate Orphan Drug Designation for the same indication.